Nova Eye Medical Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ELXMF research report →
Companynova-eye.com
Nova Eye Medical Limited designs, develops, distributes, markets, sells, and services surgical devices for the treatment of glaucoma. The company offers iTrack, a surgical system for the reduction in intraocular pressure (IOP) in adult patients with open-angle glaucoma; iTrack Advance, a natural ocular drainage system; Molteno3, a glaucoma drainage device to treat patients with severe or complex glaucoma; and 2RT, a proprietary laser technology to treat patients in early/intermediate age-related macular degeneration. It operates in Australia, the United States, Europe, the Asia Pacific, and internationally.
- CEO
- Victor Previn
- IPO
- 2010
- Employees
- 301
- HQ
- Kent Town, SA, AU
Price Chart
Valuation
- Market Cap
- $4.08M
- P/E
- -4.94
- P/S
- 1.05
- P/B
- 2.20
- EV/EBITDA
- -9.50
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 66.71%
- Op Margin
- -15.77%
- Net Margin
- -21.27%
- ROE
- -40.41%
- ROIC
- -27.99%
Growth & Income
- Revenue
- $29.27M · 25.47%
- Net Income
- $-9,059,000 · -3.06%
- EPS
- $-0.04 · 15.08%
- Op Income
- $-4,504,000
- FCF YoY
- 22.37%
Performance & Tape
- 52W High
- $0.10
- 52W Low
- $0.00
- 50D MA
- $0.01
- 200D MA
- $0.05
- Beta
- 0.94
- Avg Volume
- 81
Get TickerSpark's AI analysis on ELXMF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our ELXMF Coverage
We haven't published any research on ELXMF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ELXMF Report →